Interferon-gamma Induces Major Histocompatibility Class II Transactivator (CIITA), Which Mediates Collagen Repression and Major Histocompatibility Class II Activation by Human Aortic Smooth Muscle Cells

Overview

Journal Circ Res

Specialty Cardiology & Vascular Diseases

Date 2006 Jan 28

PMID 16439692

Citations 25

Authors

Giovanna Buttice

Janice Miller

Lin Wang

Barbara D Smith

Affiliations

Soon will be listed here.

Abstract

Chronic inflammation in atherosclerosis is responsible for plaque instability through alterations in extracellular matrix. Previously, we demonstrated that major histocompatibility class II (MHC II) transactivator (CIITA) in a complex with regulatory factor for X box 5 (RFX5) is a crucial protein mediating interferon (IFN)-gamma-induced repression of collagen type I gene transcription in fibroblasts. This article demonstrates that, in smooth muscle cells (SMCs), IFN-gamma dramatically increases the expression of CIITA isoforms III and IV, with no increase in expression of CIITA isoform I. Expression of CIITA III and IV correlates with decreased collagen type I and increased MHC II gene expression. Exogenous expression of CIITA I, III, and IV, in transiently transfected SMCs, represses collagen type I promoters (COL1A1 and COL1A2) and activates MHC II promoter. Levels of CIITA and RFX5 increase in the nucleus of cells treated with IFN-gamma. Moreover, simvastatin lowers the IFN-gamma-induced expression of RFX5 and MHC II in addition to repressing collagen expression. However, simvastatin does not block the IFN-gamma-induced expression of CIITA III and IV, suggesting a CIITA-independent mechanism. This first demonstration that RFX5 and CIITA isoforms are expressed in SMCs after IFN-gamma stimulation suggest that CIITA could be a key factor in plaque stability in atherosclerosis.

Citing Articles

Interleukin 27, like interferons, activates JAK-STAT signaling and promotes pro-inflammatory and antiviral states that interfere with dengue and chikungunya viruses replication in human macrophages.

Valdes-Lopez J, Hernandez-Sarmiento L, Tamayo-Molina Y, Velilla-Hernandez P, Rodenhuis-Zybert I, Urcuqui-Inchima S Front Immunol. 2024; 15:1385473.

PMID: 38720890 PMC: 11076713. DOI: 10.3389/fimmu.2024.1385473.

Prognostic Significance of Soluble PD-L1 on Cardiovascular Outcomes in Patients with Coronary Artery Disease.

Miyazaki S, Fujisue K, Yamanaga K, Sueta D, Usuku H, Tabata N J Atheroscler Thromb. 2023; 31(4):355-367.

PMID: 37793811 PMC: 10999719. DOI: 10.5551/jat.64183.

Genetic haplotypes associated with immune response to Leishmania infantum infection in dogs.

Alvarez L, Marin-Garcia P, Llobat L Vet Res Commun. 2023; 47(3):1675-1685.

PMID: 37059873 DOI: 10.1007/s11259-023-10123-z.

Extensive downregulation of immune gene expression by microRNA-140-3p 5' isomiR in an in vitro model of osteoarthritis.

Al-Modawi R, Brinchmann J, Karlsen T Osteoarthr Cartil Open. 2022; 3(3):100189.

PMID: 36474808 PMC: 9718227. DOI: 10.1016/j.ocarto.2021.100189.

Crosstalk Between Macrophages and Vascular Smooth Muscle Cells in Atherosclerotic Plaque Stability.

Yurdagul Jr A Arterioscler Thromb Vasc Biol. 2022; 42(4):372-380.

PMID: 35172605 PMC: 8957544. DOI: 10.1161/ATVBAHA.121.316233.

References

Harvey E, Ramji D . Interferon-gamma and atherosclerosis: pro- or anti-atherogenic?. Cardiovasc Res. 2005; 67(1):11-20. DOI: 10.1016/j.cardiores.2005.04.019. View

Kuipers H, Biesta P, Groothuis T, Neefjes J, Mommaas A, van den Elsen P . Statins affect cell-surface expression of major histocompatibility complex class II molecules by disrupting cholesterol-containing microdomains. Hum Immunol. 2005; 66(6):653-65. DOI: 10.1016/j.humimm.2005.04.004. View

Zika E, Fauquier L, Vandel L, Ting J . Interplay among coactivator-associated arginine methyltransferase 1, CBP, and CIITA in IFN-gamma-inducible MHC-II gene expression. Proc Natl Acad Sci U S A. 2005; 102(45):16321-6. PMC: 1283426. DOI: 10.1073/pnas.0505045102. View

Kwak B, Mulhaupt F, Myit S, Mach F . Statins as a newly recognized type of immunomodulator. Nat Med. 2000; 6(12):1399-402. DOI: 10.1038/82219. View

Libby P . Coronary artery injury and the biology of atherosclerosis: inflammation, thrombosis, and stabilization. Am J Cardiol. 2000; 86(8B):3J-8J; discussion 8J-9J. DOI: 10.1016/s0002-9149(00)01339-4. View

Barnes M, Farndale R . Collagens and atherosclerosis. Exp Gerontol. 2000; 34(4):513-25. DOI: 10.1016/s0531-5565(99)00038-8. View

DeSandro A, Nagarajan U, Boss J . Associations and interactions between bare lymphocyte syndrome factors. Mol Cell Biol. 2000; 20(17):6587-99. PMC: 86141. DOI: 10.1128/MCB.20.17.6587-6599.2000. View

Zhu X, Linhoff M, Li G, Chin K, Maity S, Ting J . Transcriptional scaffold: CIITA interacts with NF-Y, RFX, and CREB to cause stereospecific regulation of the class II major histocompatibility complex promoter. Mol Cell Biol. 2000; 20(16):6051-61. PMC: 86081. DOI: 10.1128/MCB.20.16.6051-6061.2000. View

Rekhter M, Hicks G, Brammer D, Hallak H, KINDT E, Chen J . Hypercholesterolemia causes mechanical weakening of rabbit atheroma : local collagen loss as a prerequisite of plaque rupture. Circ Res. 2000; 86(1):101-8. DOI: 10.1161/01.res.86.1.101. View

10.

Wong A, Brickey W, Taxman D, van Deventer H, Reed W, Gao J . CIITA-regulated plexin-A1 affects T-cell-dendritic cell interactions. Nat Immunol. 2003; 4(9):891-8. DOI: 10.1038/ni960. View

11.

Kwak B, Mulhaupt F, Veillard N, Pelli G, Mach F . The HMG-CoA reductase inhibitor simvastatin inhibits IFN-gamma induced MHC class II expression in human vascular endothelial cells. Swiss Med Wkly. 2001; 131(3-4):41-6. DOI: 10.4414/smw.2001.06144. View

12.

Reith W, MACH B . The bare lymphocyte syndrome and the regulation of MHC expression. Annu Rev Immunol. 2001; 19:331-73. DOI: 10.1146/annurev.immunol.19.1.331. View

13.

Nickerson K, Sisk T, Inohara N, Yee C, Kennell J, Cho M . Dendritic cell-specific MHC class II transactivator contains a caspase recruitment domain that confers potent transactivation activity. J Biol Chem. 2001; 276(22):19089-93. DOI: 10.1074/jbc.M101295200. View

14.

Sadeghi M, Tiglio A, Sadigh K, ODonnell L, Collinge M, Pardi R . Inhibition of interferon-gamma-mediated microvascular endothelial cell major histocompatibility complex class II gene activation by HMG-CoA reductase inhibitors. Transplantation. 2001; 71(9):1262-8. DOI: 10.1097/00007890-200105150-00014. View

15.

Waldburger J, Suter T, Fontana A, Acha-Orbea H, Reith W . Selective abrogation of major histocompatibility complex class II expression on extrahematopoietic cells in mice lacking promoter IV of the class II transactivator gene. J Exp Med. 2001; 194(4):393-406. PMC: 2193506. DOI: 10.1084/jem.194.4.393. View

16.

Zhu X, Ting J . A 36-amino-acid region of CIITA is an effective inhibitor of CBP: novel mechanism of gamma interferon-mediated suppression of collagen alpha(2)(I) and other promoters. Mol Cell Biol. 2001; 21(20):7078-88. PMC: 99883. DOI: 10.1128/MCB.21.20.7078-7088.2001. View

17.

Stefanovic B, Schnabl B, Brenner D . Inhibition of collagen alpha 1(I) expression by the 5' stem-loop as a molecular decoy. J Biol Chem. 2002; 277(20):18229-37. DOI: 10.1074/jbc.M108065200. View

18.

Mach F . Immunosuppressive effects of statins. Atheroscler Suppl. 2002; 3(1):17-20. DOI: 10.1016/s1567-5688(01)00010-1. View

19.

Jabrane-Ferrat N, Nekrep N, Tosi G, Esserman L, Peterlin B . Major histocompatibility complex class II transcriptional platform: assembly of nuclear factor Y and regulatory factor X (RFX) on DNA requires RFX5 dimers. Mol Cell Biol. 2002; 22(15):5616-25. PMC: 133954. DOI: 10.1128/MCB.22.15.5616-5625.2002. View

20.

Barbieri G, Deffrennes V, Prodhomme T, Vedrenne J, Baton F, Cortes C . Isoforms of the class II transactivator protein. Int Immunol. 2002; 14(8):839-48. DOI: 10.1093/intimm/dxf060. View